We design and deliver real-world evidence studies using Nordic registry data to generate insights on treatment patterns, outcomes, and comparative effectiveness.
Depending on the research question, this may involve pre-available datasets, targeted data requests, or fully tailored registry studies.
We develop and adapt health economic models aligned with Nordic HTA requirements, including cost-effectiveness and budget impact analyses.
Models are designed to reflect local clinical practice and can be supported by real-world data where relevant.
We support the development of evidence strategies and value communication aligned with HTA and payer expectations.
This includes defining evidence requirements, structuring analyses, and ensuring that real-world evidence and modelling outputs are positioned effectively in the decision context.
Where relevant, this work is delivered in collaboration with experienced market access partners.
In the Nordic countries, cost-effectiveness is central to reimbursement decisions. We develop robust health economic models that quantify the clinical and economic value of your product in terms decision-makers require.
Our team builds models from first principles or adapts global dossier templates to local conditions, ensuring alignment with Nordic HTA expectations. Using Excel or R — with or without interactive dashboards — we construct transparent, defensible frameworks that support reimbursement applications and strategic decision-making.
We specialize in state-transition and simulation approaches, including Markov models, to estimate long-term outcomes such as Quality-Adjusted Life Years (QALYs), costs, and budget impact. Our analyses cover cost-effectiveness and cost-benefit perspectives, producing clear incremental cost-effectiveness ratios (ICERs) and scenario analyses that withstand scrutiny from payers and policymakers.
Beyond submission support, we provide critical assessments to inform internal go/no-go decisions, pricing strategy, and market access positioning. By integrating real-world data where appropriate, we ensure models reflect clinical practice and healthcare resource use across the region.
Our goal is to deliver decision-grade evidence — enabling confident positioning when reimbursement outcomes depend on rigorous economic justification.
Access decisions increasingly depend on evidence derived from clinical practice. We develop pragmatic and observational studies using registry data, claims sources, and other real-world evidence to address the specific uncertainties identified by payers and HTA bodies.
Our team has extensive experience across the full lifecycle of evidence generation — from study design and protocol development to ethical review submissions, analysis, and scientific writing.
The Nordic healthcare registries represent one of the world’s most comprehensive sources of real-world evidence, covering a wide range of diseases and healthcare interactions over decades.
The unique personal identity number enables linkage across multiple national registries, allowing the construction of longitudinal datasets that reveal treatment patterns and outcomes not observable in most healthcare systems.
Depending on the level of detail required, available timelines, and the decision context, evidence generation can be structured in different ways.
We typically work across three approaches, ranging from rapid initial insights to fully tailored registry studies.
A short, focused engagement designed to generate evidence using pre-structured Nordic datasets.
This approach allows for rapid initiation of analyses without the need for new data requests, making it suitable when timelines are tight or when early insights are required.
Timeline: ~1 month
A structured study based on data requested from Nordic registries in aggregated or anonymized form.
This approach allows the analysis to be tailored to the specific research question while avoiding the complexity of full individual-level data access.
It provides greater flexibility and relevance compared to pre-available datasets, while maintaining more manageable timelines.
Timeline: 4-6 months
A fully tailored study based on individual-level data from one or more Nordic registries.
This approach involves data applications and ethics approval, and allows for detailed study design, linkage of multiple data sources, and advanced analyses.
It is the most comprehensive option and is used when precise, HTA-grade evidence is required.
Timeline: 6-12 months
Access decisions increasingly depend on evidence derived from clinical practice. We analyze Real-World Data (RWD) from national registries, claims sources, and epidemiological datasets to generate insights that reflect how therapies perform outside controlled trials.
Leveraging advanced statistical methods and machine learning, our team examines patterns in prescription, mortality, morbidity, and healthcare utilization across populations. We apply rigorous analytical frameworks — including regression analysis, mixed models, and longitudinal approaches — to quantify treatment effects, patient pathways, and outcomes with the precision required by payers and policymakers.
The Swedish healthcare registries represent one of the world’s most comprehensive sources of real-world evidence, covering a wide range of diseases and healthcare interactions over decades. The unique personal identity number enables linkage across multiple national registries, allowing the construction of longitudinal datasets that reveal treatment patterns and outcomes not observable in most healthcare systems.
We also maintain access to a rich catalogue of ready-to-use real-world datasets spanning epidemiology, prescription, mortality, and morbidity patterns from Swedish healthcare. Each dataset is mapped to relevant clinical indications, ICD-10 codes, drug names, and ATC codes, enabling rapid feasibility assessments for RWE and market access projects.
By transforming registry data into actionable intelligence, we help clients identify unmet needs, benchmark real-world effectiveness, and demonstrate value where it matters most — in routine clinical practice.
When existing evidence is insufficient to support reimbursement or market access, targeted evidence generation becomes essential. We design and execute studies that produce the data decision-makers need to assess your product’s clinical and economic value in real-world healthcare settings.
Our team has extensive experience across the full lifecycle of evidence generation — from study design and protocol development to ethical review submissions, analysis, and scientific writing. We develop pragmatic and observational studies using registry data, claims sources, and other real-world evidence to address the specific uncertainties identified by payers and HTA bodies.
Where appropriate, we leverage the unique capabilities of Nordic healthcare registries — particularly Sweden’s linked national datasets — to generate robust longitudinal evidence across large patient populations. This enables the assessment of outcomes, utilization, and effectiveness in routine care over time horizons that randomized trials cannot capture. This evidence reduces uncertainty for payers and HTA bodies, strengthening the case for reimbursement, pricing, and long-term adoption.
Each project is tailored to support submissions, pricing discussions, policy engagement, or strategic pivots when new circumstances emerge, delivering credible evidence that enables confident access decisions.
Client Results
Large-scale Swedish registry analysis (>600,000 patient-years) demonstrating improved glycemic outcomes and differences between automated insulin delivery systems in routine care.
“The analysis strengthened both our competitive positioning and our case for reimbursement by delivering outcomes directly relevant for HTA and payer discussions.”
© 2025 Agnostic Technology AB. All Rights Reserved.
